Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 4/20 | 0.42 |
| ▸ | CA2 | P00918 | 4/20 | 0.42 |
| ▸ | CA4 | P22748 | 4/20 | 0.42 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.42 |
| ▸ | ESR1 | P03372 | 2/20 | 0.41 |
| ▸ | MIF | P14174 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.38 |
| ▸ | PTPN1 | P18031 | 4/20 | 0.38 |
| ▸ | DPP4 | P27487 | 3/20 | 0.38 |
| ▸ | CA12 | O43570 | 3/20 | 0.38 |
| ▸ | CA3 | P07451 | 3/20 | 0.38 |
| ▸ | CA6 | P23280 | 3/20 | 0.38 |
| ▸ | CA5A | P35218 | 3/20 | 0.38 |
| ▸ | CA7 | P43166 | 3/20 | 0.38 |
| ▸ | CA9 | Q16790 | 3/20 | 0.38 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.38 |
| ▸ | CA5B | Q9Y2D0 | 3/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | GAA | P10253 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9426960 | 0.76 | CA1 (0.49) | CA1CA2CA4NFKB1ESR1 | |
| SCHEMBL6155819 | 0.76 | CA1 (0.49) | CA1CA2CA4NFKB1ESR1 | |
| Benzyl Ferulate SCHEMBL20525487 | 0.75 | CA12 (0.67) | CA1CA2CA4KDM4ECA12 | |
| SCHEMBL89143 | 0.73 | CA1 (0.57) | CA1CA2CA4NFKB1ESR1 | |
| SCHEMBL89145 | 0.73 | CA1 (0.57) | CA1CA2CA4NFKB1ESR1 | |
| SCHEMBL10041481 | 0.73 | CA1 (0.49) | CA1CA2CA4NFKB1ESR1 | |
| SCHEMBL2535854 | 0.73 | CA1 (0.52) | CA1CA2CA4NFKB1ESR1 | |
| SCHEMBL16267724 | 0.71 | CA1 (0.46) | CA1CA2CA4NFKB1ESR1 | |
| SCHEMBL6567044 | 0.70 | CA1 (0.49) | CA1CA2CA4NFKB1ESR1 | |
| SCHEMBL6567050 | 0.70 | CA1 (0.49) | CA1CA2CA4NFKB1ESR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2981254-B1 | THERAPEUTIC COMPOSITIONS COMPRISING EXTRACTS OF PROPOLIS AND USES THEREOF FOR THE TREATMENT OF GASTRIC CANCER | MANUKA HEALTH NEW ZEALAND LTD (NZ) | 2018-10-10 | — | — | EP | claimed |
| CN-105163728-B | Therapeutic compositions comprising propolis extract and uses thereof | 蜜纽康新西兰有限公司 | 2018-10-02 | — | — | CN | claimed |
| EP-2981254-A1 | THERAPEUTIC COMPOSITIONS COMPRISING EXTRACTS OF PROPOLIS AND USES THEREOF | Manuka Health New Zealand Limited (NZ) | 2016-02-10 | — | — | EP | claimed |
| US-20160030364-A1 | Therapeutic Compositions and Uses Thereof | MANUKA HEALTH NEW ZEALAND LIMITED (NZ) | 2016-02-04 | — | — | US | claimed |
| CN-105163728-A | Therapeutic compositions comprising propolis extract and uses thereof | MANUKA HEALTH NEW ZEALAND LTD | 2015-12-16 | — | — | CN | claimed |
| WO-2014163512-A1 | THERAPEUTIC COMPOSITIONS COMPRISING EXTRACTS OF PROPOLIS AND USES THEREOF | MANUKA HEALTH NEW ZEALAND LIMITED (NZ) | 2014-10-09 | — | — | WO | claimed |
| EP-3169321-B1 | PROPOLIS AND EXTRACTS THEREOF FOR THE TREATMENT OF SKIN CANCERS AND IMPROVEMENT OF SKIN HEALTH | MANUKA HEALTH NEW ZEALAND LTD (NZ) | 2020-07-15 | — | — | EP | disclosed |
| EP-2981254-B1 | THERAPEUTIC COMPOSITIONS COMPRISING EXTRACTS OF PROPOLIS AND USES THEREOF FOR THE TREATMENT OF GASTRIC CANCER | MANUKA HEALTH NEW ZEALAND LTD (NZ) | 2018-10-10 | — | — | EP | disclosed |
| CN-105163728-B | Therapeutic compositions comprising propolis extract and uses thereof | 蜜纽康新西兰有限公司 | 2018-10-02 | — | — | CN | disclosed |
| CN-105163728-B | Therapeutic compositions comprising propolis extract and uses thereof | 蜜纽康新西兰有限公司 | 2018-10-02 | — | — | CN | disclosed |
| US-20170209499-A1 | Propolis and Extracts Thereof for the Treatment of Skin Cancers and Improvement of Skin Health | MANUKA HEALTH NEW ZEALAND LIMITED (NZ) | 2017-07-27 | — | — | US | disclosed |
| EP-3169321-A1 | PROPOLIS AND EXTRACTS THEREOF FOR THE TREATMENT OF SKIN CANCERS AND IMPROVEMENT OF SKIN HEALTH | Manuka Health New Zealand Limited (NZ) | 2017-05-24 | — | — | EP | disclosed |
| EP-2981254-A1 | THERAPEUTIC COMPOSITIONS COMPRISING EXTRACTS OF PROPOLIS AND USES THEREOF | Manuka Health New Zealand Limited (NZ) | 2016-02-10 | — | — | EP | disclosed |
| US-20160030364-A1 | Therapeutic Compositions and Uses Thereof | MANUKA HEALTH NEW ZEALAND LIMITED (NZ) | 2016-02-04 | — | — | US | disclosed |
| US-20160030364-A1 | Therapeutic Compositions and Uses Thereof | MANUKA HEALTH NEW ZEALAND LIMITED (NZ) | 2016-02-04 | — | — | US | disclosed |
| WO-2016010440-A1 | PROPOLIS AND EXTRACTS THEREOF FOR THE TREATMENT OF SKIN CANCERS AND IMPROVEMENT OF SKIN HEALTH | MANUKA HEALTH NEW ZEALAND LIMITED (NZ) | 2016-01-21 | — | — | WO | disclosed |
| CN-105163728-A | Therapeutic compositions comprising propolis extract and uses thereof | MANUKA HEALTH NEW ZEALAND LTD | 2015-12-16 | — | — | CN | disclosed |
| CN-105163728-A | Therapeutic compositions comprising propolis extract and uses thereof | MANUKA HEALTH NEW ZEALAND LTD | 2015-12-16 | — | — | CN | disclosed |
| WO-2014163512-A1 | THERAPEUTIC COMPOSITIONS COMPRISING EXTRACTS OF PROPOLIS AND USES THEREOF | MANUKA HEALTH NEW ZEALAND LIMITED (NZ) | 2014-10-09 | — | — | WO | disclosed |
| WO-2014163512-A1 | THERAPEUTIC COMPOSITIONS COMPRISING EXTRACTS OF PROPOLIS AND USES THEREOF | MANUKA HEALTH NEW ZEALAND LIMITED (NZ) | 2014-10-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160030364-A1 | Therapeutic Compositions and Uses Thereof | TEC, FABP6, PGC | CA1 1469/4885CA2 1484/4885CA4 303/4885 |
| US-20170209499-A1 | Propolis and Extracts Thereof for the Treatment of Skin Cancers and Improvement of Skin Health | CUTA, DSC1, DACH1 | CA1 3542/4885CA2 2395/4885CA4 964/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.